tbuckley/cabot-search huggingface dataset:
Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Xiyuan Zhang, Katherine L. Cook, Anni Warri, Idalia M. Cruz, Mariana Rosim, Jeffrey Riskin, William Helferich, Daniel Doerge, Robert Clarke, Leena Hilakivi-Clarke
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Whether it is safe for estrogen receptor–positive (ER+) patients with breast cancer to consume soy isoflavone genistein remains controversial. We compared the effects of genistein intake mimicking either Asian (lifetime) or Caucasian (adulthood) intake patterns to that of starting its intake during tamoxifen therapy using a preclinical model. Experimental Design: Female Sprague-Dawley rats were fed an AIN93G diet supplemented with 0 (control diet) or 500 ppm genistein from postnatal day 15 onward (lifetime genistein). Mammary tumors were induced with 7,12-dimethylbenz(a)anthracene (DMBA), after which a group of control diet–fed rats were switched to genistein diet (adult genistein). When the first tumor in a rat reached 1.4 cm in diameter, tamoxifen was added to the diet and a subset of previously only control diet–fed rats also started genistein intake (post-diagnosis genistein). Results: Lifetime genistein intake reduced de novo resistance to tamoxifen, compared with post-diagnosis genistein groups. Risk of recurrence was lower both in the lifetime and in the adult genistein groups than in the post-diagnosis genistein group. We observed downregulation of unfolded protein response (UPR) and autophagy-related genes (GRP78, IRE1α, ATF4, and Beclin-1) and genes linked to immunosuppression (TGFβ and Foxp3) and upregulation of cytotoxic T-cell marker CD8a in the tumors of the lifetime genistein group, compared with controls, post-diagnosis, and/or adult genistein groups. Conclusions: Genistein intake mimicking Asian consumption patterns improved response of mammary tumors to tamoxifen therapy, and this effect was linked to reduced activity of UPR and prosurvival autophagy signaling and increased antitumor immunity. Clin Cancer Res; 23(3); 814–24. ©2017 AACR.
Involvement of matrix metalloproteinases in chronic Q fever
Authors: A.F.M. Jansen, T. Schoffelen, J. Textoris, J.L. Mege, C.P. Bleeker-Rovers, H.I.J. Roest, P.C. Wever, L.A.B. Joosten, M.G. Netea, E. van de Vosse, M. van Deuren
Journal: Clinical Microbiology and Infection (2017)
Designing and implementing a payment system to support cancer care coordination: A literature review.
Authors: Anne Girault, Chloe Gerves-Pinquie, Etienne Minvielle
Journal: Journal of Clinical Oncology (2016)

40 Background: Demands for new payment systems to better coordinate services along the care continuum are emerging in oncology. Among them, bundling payments for defined episodes of care are considered as a promising payment option. The study objective was to understand how to develop an optimal payment system in order to foster coordination between hospitals and post-acute providers, and to identify potential pitfalls associated with its implementation. Methods: We conducted a literature review, exploring articles published between 2010 and 2015 in Medline. 47 papers were finally retrieved, including 18 articles focusing on cancer care. Results: The review highlighted key issues in the design and implementation of an alternative payment model in oncology. First, some studies explained that the level of integration of the different stakeholders would condition the choice of the payment design. They advised that the enrolled caregivers had a prior experience of working together so that the payment could rely on already formalized care processes. Second, most papers insisted that healthcare professionals had to be included since the design phase to agree on a standardized care pathway that would be consistent with current guidelines. To do so, focus groups and semi-structured interviews conducted with professionals from the enrolled facilities, as well as payers and patient associations, were favored. Third, the review showed that economic evaluations were necessary to have an understanding of the episode costs and determine gain-sharing arrangements between caregivers as well as their respective financial accountability. Using a micro-costing approach and adopting a societal perspective to estimate direct, indirect and intangible costs were demanded. Contingent evaluations measuring professionals’ willingness to participate in the payment scheme could serve as complementary analyses. Conclusions: The adoption of a new payment system would be strongly dependent on the design choices and implementation processes. A pilot study assessing its effectiveness in cancer care should bring important knowledge for policymakers willing to develop value-based payment systems in oncology.
A new gastric balloon for weight loss that eliminates the need for endoscopy – good news for the bariatrician
Authors: Steven Edmundowicz, Sullivan Shelby
Journal: Endoscopy (2017)

The world is in the midst of an obesity epidemic that appears to be growing [1] despite recent advances in pharmacology and new endoscopic obesity treatment options. Gastric balloons have been available worldwide to treat obesity for over two decades. Typically, their use would involve endoscopic placement and removal and concomitant exposure to a moderately intense lifestyle program that involves at least monthly visits to the individuals delivering the lifestyle therapy. Recently an ingested gas-filled balloon has been approved for use in the United States that eliminates the necessity for endoscopic placement [2]. In this issue of Endoscopy, Machtyka et al. [3] describe an open-label trial of an innovative new balloon that is ingested and then filled with fluid once its position is confirmed in the stomach. The patient undergoes lifestyle therapy with the benefit of the gastric balloon for 4 months. Then the balloon spontaneously deflates and is passed through the gastrointestinal (GI) tract; the entire therapy is thus completed without endoscopy.
A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metasetatic or recurrent pancreatic cancer.
Authors: Sun Jin Sym, Junsik Hong, Minkyu Jung, Yang Seo Koo, Yeon Ho Park, Koen Kook Kim, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Dong Bok Shin
Journal: Journal of Clinical Oncology (2012)

e14685 Background: Treatment with single agent gemcitabine provides modest benefits in patients with metastatic pancreatic cancer.This study was performed to determine the efficacy of gemcitabine in combination with oxaliplatin and capecitabine in patient with recurrent or metastatic pancreatic adenocarcinoma. Methods: This was a prospective, single-arm, single center study in patients with chemotherapy-naive metastatic or recurrent pancreatic adenocarcinoma. The primary endpoint was objective response. The study was designed as a Simons two-stage optimal design and was divided into two stages. The first stage was to recruit up to 18 patients. If at least two objective responses were obtained, then a further 25 patients would be enrolled into the study. If no more than two responses were obtained among these 18 patients, the study would be halted. The study patients received gemcitabine 800 mg/m 2 on day1, plus oxaliplatin 100 mg/m 2 on day 1 and capecitabine 800 mg/m 2 /day on days 1-7 every 14 days. Treatment was to be administered until disease progression or until withdrawal from the study due to unacceptable toxicity or other reasons. Results: Eighteen patients were enrolled. Median age was 63 years (range, 39-73 years). Among these 18 patients, only one patient (5.5%) achieved an objective response. Therefore, the accrual terminated. The median time to disease progression was 2.1 months, and the median overall survival duration was 4.9 months. One-year overall survival rates were 35.3%. The most frequently reported grade 3 or 4 adverse events were asthenia (16.6%), and nausea (5.5%). There were no unexpected toxicities. Conclusions: The addition of oxaliplatin and capecitabine to gemcitabine did not improve objective response in the first-line treatment of advanced pancreatic cancer patients.
Efficient Expansion of Lymphocytes in a Culture System with Solid Phase Anti-CD3 and Anti-CD28 Monoclonal Antibodies.
Authors: Atsuko Soeda, Atsushi Kondo, Hiroaki Makiyama, Yuriko Morita, Noriko Takahashi, Hideo Yagita, Yoichi Takaue, Yuji Heike
Journal: Blood (2006)
Inflammatory Cell Tissue Extravasation Pathways Can Be Regulated by Adherent Stem Cells by Inhibiting Selectin Ligand and Adhesion Receptor Expression On T Cells and Activated Endothelium.
Authors: Wouter Van't Hof, Amy Raber, Juliana Woda, Nicholas Lehman, Rochelle Cutrone, Anthony Ting, Robert Deans
Journal: Blood (2009)
Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib
Authors: Yosuke Minami, Akihiro Abe, Yuka Nomura, Miho Minami, Yachiyo Kuwatsuka, Kunio Kitamura, Junji Hiraga, Shinichi Mizuno, Kazuhito Yamamoto, Tomohiro Kajiguchi, Masashi Sawa, Yuichiro Inagaki, Toshiya Yokozawa, Etsuko Aoki, Kazutaka Ozeki, Keisuke Watanabe, Koichi Miyamura, Hitoshi Kiyoi, Tomoki Naoe
Journal: Blood (2010)
Association of Functional Single Nucleotide Variation in the NLRP3 Gene with Survival Outcomes After Unrelated Bone Marrow Transplantation.
Authors: Akiyoshi Takami, J. Luis Espinoza, Keitaro Matsuo, Yasuo Morishima, Makoto Onizuka, Koichi Kashiwase, Takahiro Fukuda, Yoshihisa Kodera, Shinji Nakao
Journal: Blood (2012)
Complexity of Clonal Architecture in Childhood Acute Lymphoblastic Leukaemia
Authors: Kristina Anderson, Christoph Lutz, Frederik W. van Delft, Sue Colman, Yanping Guo, Helena Kempski, Anthony . Moorman, Tariq Enver, John Swansbury, Lyndal Kearney, Mel Greaves
Journal: Blood (2009)
Effect of IKZF1 Deletions on Signal Transduction Pathways in Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Authors: Naomi E van der Sligte, Frank JG Scherpen, Arja ter Elst, Victor Guryev, Frank N van Leeuwen, Evelina SJM de Bont
Journal: Blood (2014)
Regulation of Transcription Factors Foxp1, E2A and Egr-1 By microRNA-191 Constrains B Lymphocyte Development and Suppresses Development of Diffuse Large B Cell Lymphoma
Authors: Marcin Lyszkiewicz, Jonas Blume, Natalia Zietara, Katrin Witzlau, Jacek Puchalka, Namita Saran, Sandra Duber, Roy Bishnudeo, Siegfried Weiss, Andreas Krueger
Journal: Blood (2015)
Flow Cytometry and Immunohistochemistry Analyses Reveal That Rituximab/CD20 Complexes Are Removed (Shaved) from Mantle Cell Lymphoma Cells (Z138) Previously Infused Intravenously or Subcutaneously in a SCID Mouse Model, and the Shaving Reaction Can Be Blocked by IVIG.
Authors: Ronald P. Taylor, Yongli Li, Margaret A. Lindorfer, John B. Coursar, Michael E. Williams
Journal: Blood (2006)
Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit
Authors: Kathryn Oakland, Richard Guy, Raman Uberoi, Rachel Hogg, Neil Mortensen, Michael F Murphy, Vipul Jairath
Journal: Gut (2017)

<h3>Objective</h3> Lower GI bleeding (LGIB) is a common reason for emergency hospital admission, although there is paucity of data on presentations, interventions and outcomes. In this nationwide UK audit, we describe patient characteristics, interventions including endoscopy, radiology and surgery as well as clinical outcomes. <h3>Design</h3> Multicentre audit of adults presenting with LGIB to UK hospitals over 2 months in 2015. Consecutive cases were prospectively enrolled by clinical teams and followed for 28 days. <h3>Results</h3> Data on 2528 cases of LGIB were provided by 143 hospitals. Most were elderly (median age 74 years) with major comorbidities, 29.4% taking antiplatelets and 15.9% anticoagulants. Shock was uncommon (58/2528, 2.3%), but 666 (26.3%) received a red cell transfusion. Flexible sigmoidoscopy was the most common investigation (21.5%) but only 2.1% received endoscopic haemostasis. Use of embolisation or surgery was rare, used in 19 (0.8%) and 6 (0.2%) cases, respectively. 48% patients underwent no inpatient investigations. The most common diagnoses were diverticular bleeding (26.4%) and benign anorectal conditions (16.7%). Median length of stay was 3 days, 13.6% patients rebled during admission and 4.4% were readmitted with bleeding within 28 days. In-hospital mortality was 85/2528 (3.4%) and was highest in established inpatients (17.8%, p&lt;0.0001) and in patients experiencing rebleeding (7.1%, p&lt;0.0001). <h3>Conclusions</h3> Patients with LGIB have a high burden of comorbidity and frequent antiplatelet or anticoagulant use. Red cell transfusion was common but most patients were not shocked and required no endoscopic, radiological or surgical treatment. Nearly half were not investigated. In-hospital mortality was related to comorbidity, not severe haemorrhage.
Frequent Inactivating Mutations of TET2 and CBL Are Associated with Acquired Uniparental Disomy in Atypical Chronic Myeloid Leukemia and Related Disorders.
Authors: Thomas Ernst, Andrew Chase, Claire Hidalgo-Curtis, Katerina Zoi, Christine Zoi, Andreas Hochhaus, Andreas Reiter, William Vainchenker, Francis Grand, Nicholas C.P. Cross
Journal: Blood (2009)
A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML).
Authors: Alfonso Quintas-Cardama, Hagop M. Kantarjian, William Wierda, Alessandra Ferrajoli, Rong Chen, Farhad Ravandi, William Plunkett, Jorge Cortes
Journal: Blood (2006)
Abstract 14308: Parameters of Exercise Stress Testing Are Associated With Incident Major Cardiovascular Event independent of Risk Factors and Coronary Artery Calcification - The Heinz Nixdorf Recall Study
Authors: Amir A Mahabadi, Nils Lehmann, Hagen Kälsch, Noreen Pundt, Iryna Dykun, Susanne Moebus, Karl-Heinz Jöckel, Raimund Erbel, Stefan Möhlenkamp
Journal: Circulation (2015)

Objective: To assess the prognostic value of parameters of autonomic cardiac function and cardiovascular fitness, as derived from exercise stress ECG testing, in addition to traditional risk factors and the anatomic information of coronary artery calcification (CAC)-score. Methods: Participants from the population based Heinz Nixdorf Recall Study without known cardiovascular disease and without heart rate lowering therapy were included. CAC-score was quantified from non-contrast electron beam CT. From bicycle stress ECG testing peak heart rate (HR), HR recovery (decline of HR 1 minute after peak exercise), exercise capacity, exercise duration, and chronotropic incompetence (chronotropic response of ≤80%) were assessed. We determined gender differences of exercise parameters. Associations with cardiovascular events (myocardial infarction, stroke, cardiovascular death) were evaluated using multivariable Cox regression. Results: We included 2349 subjects (age 58.1 ± 7.4 years, 48% male). Exercise duration and exercise capacity were higher in men (11.6 ± 3.0 vs. 7.6 ± 1.9 min, p&lt;0.0001 and 8.9 ± 1.9 vs. 6.5 ± 1.3 METs, p&lt;0.0001), while peak HR, HR recovery, and frequency of chronotropic response were not significantly different between gender (p&gt;0.05). During a median (Q1; Q3) follow-up of 10.6 (10.2; 11.4) years, 118 cardiovascular events occurred. Adjusting for Framingham risk score, peak HR (0.70 (0.52-0.95), p=0.02), HR recovery (0.70 (0.50-0.98), p=0.04), exercise capacity (0.64 (0.45-0.92), p=0.01), and chronotopic incompetence (2.62 (1.35-5.06), p=0.004) were associated with events in women, while only exercise duration was significantly associated in men (0.77 (0.60-0.99), p=0.04). When ancillary adjusting for CAC-score, exercise duration was associated with events in both genders (women: 0.67 (0.47-0.96), p=0.03, men: 0.61 (0.43-0.87), p=0.007), while chronotropic incompetence (2.43 (1.25-4.70), p=0.01) and exercise capacity (0.69 (0.48-0.99), p=0.04) were significantly associated in women only. Conclusion: Parameters of exercise stress ECG testing are associated with incident major cardiovascular events, independent of traditional risk factors and coronary artery calcification, especially in female subjects.
Pure Red Cell Aplasia Associated with Plasma Cell Myeloma: Does Monoclonal Protein Inhibit Erythropoiesis?
Authors: Neha Korde, Kelsey Loeliger, Olga Simakova, Adriana Zingone, Richard Childs, Ola Landgren, Pierre Noel, Elaine M Sloand, Irina Maric
Journal: Blood (2010)
Biomolecular characterization of formalin-fixed paraffin-embedded primary renal tumor specimens.
Authors: Vanessa Medina, Guadalupe Aparicio Gallego, Isabel Santamarina, Manuel Valladares Ayerbes, Luis M. Antón Aparicio
Journal: Journal of Clinical Oncology (2012)

421 Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer. It is required a better understanding of signalling pathways involved in renal cells. Methods: We assessed using immunohistochemistry (IHC) and quantitative real-time PCR (qPCR) with SYBR Green the profile of predictive markers involved in the cascade of events leading to the formation and progression: invasiveness, angiogenesis and antiapoptotic mechanisms. 80 RCC tissues were detected by IHC. RNA of quality only was obtained in 72 (80% clear RCC, 10% papillary RCC and 10% chromophobe RCC) to carry out the study of gene expression through qPCR. A pool of normal kidney-derived RNA samples (N=5) was used as healthy control. GAPDH and YWHAZ were used as reference genes. GenEx software was used for qPCR data processing and analysis. Nonparametric tests (Pearson’s correlation coefficient test and Spearman’s rho test, Kruskal — Wallis and Mann — Whitney) were applied for statistical data analysis (SPSS 19). Results: p53 showed higher expression in those cases with Furhman grade I (p=0.036). Moreover p53 showed a positive association with VEGF, GLUT1, GLUT4, VEGFR-2 and VHL (r=0.241, sig. level 0.05; r=0.291, sig. level 0.01; r=0.456, sig. level 0.01; r=0.187, sig. level 0.097 and Spearman’s rho=0.269, sig. level 0.05 respectively). Hif1- α, Hif1- β, Notch1 and Notch3 were upregulated in chromophobe RCC (p=0.045, p=0.03, p=0.03 and p=0.02 respectively). Hif1- α and Notch3 were upregulated in clear RCC (p=0.034 and p=0.041 respectively). Spearman’s correlation coefficient showed a strong positive correlation between Nocth1-4 members and their receptors and Hif1-α and β genes. Highlight the correlation found between: Notch1 and Hif1-α (Spearman’s rho = 0.740, significance level 0.01) and Hif1-β and Jagged1 (Spearman’s rho = 0.752, significance level 0.01). Conclusions: The pathway involving the tumor suppressor gene p53 could regulate tumor angiogenesis. Co-expression of Notch receptors, their ligands and Hif-1 α and Hif1- β subunits may play a role in human RCC. Notch cascade may represent a novel and therapeutically accessible pathway in chromophobe and clear RCC. More detailed studies of these crossing pathways are in progress.
Knocking down amygdalar PTP1B in diet-induced obese rats improves insulin signaling/action, decreases adiposity and may alter anxiety behavior
Authors: Natalia Ferreira Mendes, Gisele Castro, Dioze Guadagnini, Natalia Tobar, Susana Quiros Cognuck, Lucila Leico Kagohara Elias, Patricia Aline Boer, Patricia Oliveira Prada
Journal: Metabolism (2017)
PBSCT Similar to BMT Allows Active B-Lymphopoiesis Unless Severe GVHD Occurs.
Authors: Julia Winkler, Armin Biller, Natalie Schub, Wolf Rösler, Kerstin Eckart-Schäfer, Hannes Wandt, Claudia N. Kluender, Rainer Schwerdtfeger, Joachim Hahn, Ernst Holler, Thomas H. Winkler, Martin Gramatzki
Journal: Blood (2005)
Denying Visas to Doctors in the United States
Authors: Muhammad H Majeed, Fahad Saeed
Journal: New England Journal of Medicine (2017)

To the Editor: Marso et al. report diabetic retinopathy complications in patients with type 2 diabetes who received semaglutide; this raises the possibility that GLP-1-receptor agonists could cause progression of diabetic retinopathy.The authors cite seminal studies involving patients with type 1 diabetes and suggest that progression of diabetic retinopathy is due to the glucoselowering effect of treatment. 1Studies involving patients with type 2 diabetes, 2,3 albeit smaller and retrospective, also have shown similar find-The New England Journal of Medicine Downloaded from nejm.org
薬物溶出ステント留置術後のステント血栓症(SAT/LST/VLST)の予測因子
Authors: Takama Takurou, Muramatsu Toshiya, Tsukahara Reiko, Itoh Yoshiaki, Sakai Tsuyoshi, Ishimori Hiroshi, Hirano Keisuke, Nakano Masatsugu, Yamawaki Masahiro, Araki Motoharu, Sasaki Shinya, Takimura Hideyuki, Sakamoto Yasunari, Komatsu Ikki
Journal: Circulation (2011)
Factor H Binds to Von Willebrand Factor (VWF) and Regulates Its Cleavage by ADAMTS-13
Authors: Miguel A. Cruz, Francisca C. Gushiken, Rolando Rumbaut, Kavita N Patel, Nancy Turner, Leticia Nolasco, Hyojeong Han, Matthew Pickering, Jing-fei Dong, Joel L. Moake, Vahid Afshar-Kharghan
Journal: Blood (2008)
Inhibitory effect of norcantharidin, a demethylated form of cantharidin, on HL-60 cells in vitro
Authors: Lijian Xian
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4068 

Abstract: Norcantharidin (NCTD) is a demethylated form of cantharidin with antitumor properties, which is now used as a routine anticancer drug in China. However, there is limited information on the effect of NCTD on human cancer cells. In the present study, NCTD inhibited proliferation and DNA replication, caused mitotic arrest, and induced apoptosis in HL-60 cells. NCTD treatment resulted in cleavage of Cdc6, a replication-initiation protein, in HL-60 and HepG2 cells. At the concentration of 50 μM, NCTD cleaved Cdc6 after 12 h treatment, producing a fragment about 49KD, and prolonged treatment with NCTD resulted in complete degradation and loss of Cdc6. However, another initiation protein Cdc45 showed no change after NCTD treatment. NCTD induced remarkable G2/M arrest in HL-60 cells. Treatment with NCTD decreased the expression of Cdc25C and CyclinB1 but did not affect the expression of Cdk1. Furthermore, typical apoptotic features including the morphological changes and DNA fragmentation were observed in NCTD-treated cells. In addition, NCTD treatment caused activation of caspase3, preceding DNA fragmentation and morphologic features of apoptosis. Pretreatment with the special caspase3 inhibitor Ac-DEVD-cho markedly inhibited NCTD-induced caspase3 activity and cell death. In conclusion, these results reveal that NCTD inhibit DNA replication and induce apoptosis in cancer cells, which account for its anticancer effect. The cleavage of Cdc6 may contribute to NCTD-induced DNA replication inhibition, and occur in association with apoptosis. Furthermore, down-expression of Cdc25C and CyclinB1 may be the molecular mechanism through which NCTD induces G2/M arrest.Key words: Norcantharidin; DNA replication; G2/M arrest; Apoptosis;
Pre-Transplant Biomarkers Predict GVHD and Treatment-Related Mortality in Patients Treated with Extracorporeal Photopheresis Prior to Allogeneic Bone Marrow Transplantation.
Authors: Peter J. O’Brien, Brian Bolwell, Sunil Abhyankar, Paul Shaughnessy, Koen van Besien, Paul Williamson, Kim A. Campbell
Journal: Blood (2006)
Gender differences in clinical characteristics of first-admission psychotic depression
Authors: S Fennig, E Bromet, L Jandorf
Journal: American Journal of Psychiatry (1993)

The authors explored differences in the clinical characteristics of 17 male and 13 female patients experiencing their first admission for psychotic depression. Few differences were observed for most depressive and psychotic features, but fewer male than female patients reported fatigue, psychomotor agitation, and systematized and mood-incongruent delusions and more male patients reported feelings of worthlessness. Overall, the findings were consistent with those derived from samples of patients with chronic, nonpsychotic mental illness.